The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NRG1 fusions in non–small cell lung cancer (NSCLC): Prevalence, clinical and molecular features from a real-world cohort profiled with DNA plus RNA-based sequencing.
 
Breno Araujo
No Relationships to Disclose
 
Filipe Visani
No Relationships to Disclose
 
Rafael Paes
No Relationships to Disclose
 
Christopher Negrete
No Relationships to Disclose
 
Nathalia Correa
No Relationships to Disclose
 
Fernanda Koyama
No Relationships to Disclose
 
Pedro Kuhner
No Relationships to Disclose
 
Jessica de Assis
No Relationships to Disclose
 
Luciana Valverde
No Relationships to Disclose
 
Carolina de Bustamante Fernandes
No Relationships to Disclose
 
Clarissa Mathias
No Relationships to Disclose
 
Mariana Laloni
No Relationships to Disclose
 
Tatiane Montella
No Relationships to Disclose
 
Carlos Moreira Ferreira
Employment - Oncoclinicas & Co
Stock and Other Ownership Interests - Oncoclinicas & Co
Consulting or Advisory Role - AstraZeneca; BeiGene
Speakers' Bureau - BeiGene
 
William William
Employment - Grupo Oncoclinicas
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Janssen; Lilly; Merck; Novartis; Pfizer; Regeneron; Roche/Genentech; Sanofi/Aventis; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Merck; Pfizer; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); OSI Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Merck; Roche/Genentech
 
Rodrigo Dienstmann
Employment - Oncoclínicas
Stock and Other Ownership Interests - Trialing Health
Consulting or Advisory Role - AstraZeneca; Foundation Medicine; Roche
Speakers' Bureau - Amgen; AstraZeneca; Gilead Sciences; GlaxoSmithKline; Ipsen; Janssen Oncology; Libbs; Lilly; MSD Oncology; Pfizer; Roche; Sanofi; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Merck; Merck Serono (Inst); Novartis (Inst); Pfizer (Inst)